|Bid||7,237.00 x 0|
|Ask||7,237.00 x 0|
|Day's Range||7,159.00 - 7,356.00|
|52 Week Range||109.51 - 8,227.88|
|Beta (3Y Monthly)||0.23|
|PE Ratio (TTM)||45.47|
|Earnings Date||Oct 24, 2019|
|Forward Dividend & Yield||2.19 (3.01%)|
|1y Target Est||78.83|
AstraZeneca Plc said on Monday its experimental treatment significantly reduced disease activity in patients with autoimmune disorder lupus, in a late-stage study. The results pit the British drugmaker's anifrolumab against rival GlaxoSmithKline Plc's Benlysta - the only new drug approved for lupus in the last 60 years. Benlysta recorded 473 million pounds of global sales in 2018, up 26% from a year earlier.
These stocks are expected to new release products or services in the next year with massive sales potential, per analysis by Bloomberg Intelligence.
AstraZeneca said that safety data on roxadustat underpinned the British drugmaker's hopes for the anaemia drug to become a standard treatment for patients with kidney disease. It said pooled data from several late-stage trials showed that roxadustat did not increase the risk of potentially deadly cardiovascular complications like heart attacks and strokes when used instead of epo, which is the standard treatment for dialysis patients against lack of red blood cells from kidney disease. For a subgroup of patients that had just recently gone on dialysis the cardiovascular risk was about one third lower for patients on roxadustat compared with those on epo, it added.
Biopharmaceutical companies invest millions of dollars in their clinical pipeline, chasing that one elusive cure that can fetch them manifold returns when the program comes to fruition. Often times, unfazed ...
Top Indian drugmaker Sun Pharmaceutical Industries Ltd said on Wednesday Britain's AstraZeneca would distribute some of Sun's cancer treatment drugs in China, the world's second-largest pharmaceutical market. As per the licensing agreement, Sun will be responsible for development, regulatory filings and manufacturing of the drugs, while AstraZeneca will exclusively promote and distribute the products in China, according to a filing https://www.bseindia.com/xml-data/corpfiling/AttachLive/e10d3bee-3ab1-4a0f-ab45-600f16796260.pdf to Indian stock exchanges.
AstraZeneca said it is lauching a new fund with China International Capital Corporation (CICC) to invest $1 billion (£777.00 million) in China's healthcare sector, as it expands its research work in the country. The fund would look to invest in Chinese firms, with companies in a life-sciences park it helped open in the eastern city of Wuxi last year to be among its first beneficiaries, the British drugmaker's chief executive officer, Pascal Soriot, told Reuters. AstraZeneca was a minority partner in the fund and would mainly play an advisory role in selecting investments and supporting the firms, he said.
AstraZeneca has signalled its confidence in China’s biotech sector by partnering state-owned investment bank CICC on a $1bn fund to invest in local start-ups. The Anglo-Swedish drugmaker would contribute a “substantial” amount to the fund, which would have Singaporean sovereign wealth fund Temasek as a partner, and would finance mainly “smaller ventures,” said Pascal Soriot, chief executive. It would be AstraZeneca’s largest fund, Mr Soriot said, adding that he expected it would reach its target within four years.
Investing in pharmaceutical companies is never easy. But with Biogen (NASDAQ:BIIB), that sentiment is multiplied a hundred fold. A nasty part of this business is that everything rides on key, flagship drugs. With science being the ultimate skeptic, passing clinical muster is an absolute. And Biogen stock demonstrated how critical this concept is within this year.Source: Shutterstock At the start of 2019, BIIB stock got off to a quick lead. Although shares have been frustratingly choppy over the trailing five years, Biogen did have one ace up its sleeve: aducanumab. A groundbreaking drug designed to slow cognitive decline in some Alzheimer's disease patients, Biogen began conducting clinical trails a few years back.However, in March of this year, the pharmaceutical halted two late-stage trails for aducanumab. Unfortunately for both Biogen engineers and hopeful patients, an independent audit revealed that the drug was likely ineffective. Upon the news, Biogen stock collapsed more than 29%.InvestorPlace - Stock Market News, Stock Advice & Trading TipsAnd between that point and Oct. 21, BIIB stock really didn't move much. Everything hinged on aducanumab, which represented - excuse the expression - a pharmaceutical cash cow. * 7 Stocks to Buy in November However, that same failed drug was responsible for a massive upswing in Biogen stock a day later on Oct. 22. Essentially, the Food and Drug Administration gave the green light for the underlying company to reapply for aducanumab's approval.Going on the media circuit, Biogen CEO Michel Vounatsos expressed confidence that this time, aducanumab will receive FDA approval. But how likely is such an event, and how should investors approach BIIB stock?We'll take a look at the good, the bad, and the ugly. The Good News for Biogen StockAccording to Vounatsos, the key reason why aducanumab failed was due to a small sample size. Additionally, the first round of clinical trials did not feature dosage diversity. Basically, Biogen did not give patients a strong enough dosage.However, a new analysis on a much larger data set with the higher dosages revealed a stronger mitigation of Alzheimer's disease symptoms. This encouraged Biogen to discuss the fresh findings with the FDA, leading to the green light to reapply.Of course, this does not guarantee that aducanumab will ultimately receive FDA approval. There's a big difference between applying for an Ivy League school and getting into one. And while Vounatsos has emphasized his confidence, I would expect that from any CEO.Still, it gives aducanumab a chance. For now, that's all investors need, having pushed BIIB stock roughly to where it was a year ago.But there's also a human component to aducanumab. The Alzheimer's Association estimates that 5.8 million Americans suffer from the disease. Further, it's the sixth leading cause of death in the U.S. If aducanumab works as advertised this time around, it would represent a medical breakthrough.Plus, with so many people suffering from Alzheimer's, Biogen stock will be worth its weight in gold. The Bad News for BIIBAlthough the enthusiasm is palpable for Biogen stock, investors should take a breather before acting on it. As with any equity, you don't want to jump in after a big move without some serious thought.While the reasons forwarded for why the first trial of aducanumab failed makes sense, it doesn't necessarily mean that this latest analysis implies a tangible success for the drug. And investors, medical researchers and patients have reasons to be skeptical.Indeed, I would guess that any intellectually honest medical doctor would advise his or her patient to keep grounded. First, no one outside of Biogen has seen the details of this larger data set analysis. Thus, without peer review, it's hard to generate much excitement.As Dr. Michael Weiner, Alzheimer's researcher at the University of California, San Francisco, told the New York Times, aducanumab could spark "the dawn of a new era." However, Weiner noted that this is not a cure, but rather, "It is a slowing of decline. The practical impact on patients remains to be seen."Not only that, research for Alzheimer's and other dementia-related diseases is littered with failure. Roche (OTCMKTS:RHHBY), Eli Lilly (NYSE:LLY), AstraZeneca (NYSE:AZN), Pfizer (NYSE:PFE) and Merck (NYSE:MRK) have all abandoned this market.You can look at it two ways for BIIB stock: it's a massive opportunity if the company wins, but that probability is very, very low. And Finally, the UglyThus, comes the million-dollar question: how should investors approach Biogen stock?Here's the ugly truth: I have no idea. And I suspect that most analysts feel the same.Without the peer-reviewed analysis of Biogen's new study, investors are operating in the dark. Therefore, if I had to make a guess, I would rely on what we do know. And that is Alzheimer's treatments have a bad track record.Even Biogen's initial clinical trial failed when held to an independent audit. Therefore, BIIB has the credibility hurdle. Given that we won't know the details for some time, gambling on Biogen stock right now seems risky.As of this writing, Josh Enomoto did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Buy-and-Hold Stocks to Play Investing's Biggest Trends * 7 Stocks to Buy in November * 5 Strong Buy Stocks Under $5 With Massive Upside Potential The post The Good, Bad, and Ugly for Biogen Stock appeared first on InvestorPlace.
Merck & Co Inc on Tuesday said it expected immunotherapy Keytruda to continue its market dominance as an initial treatment for advanced lung cancer as sales of the drug topped $3 billion in a quarter for the first time, beating lofty Wall Street estimates. Merck shares rose more than 2% to $84 in early trading. Keytruda has become the go to treatment for newly diagnosed advanced lung cancer, with eight out of 10 eligible U.S. patients now receiving the therapy.
The triple combo of Imfinzi, tremelimumab and chemotherapy also met the key secondary endpoint of showing a statistically significant and clinically meaningful PFS improvement vs. chemotherapy alone, AstraZeneca said in a statement.
AstraZeneca Plc said on Monday a combination of its cancer drug, Imfinzi, along with chemotherapy helped curb progression of lung cancer in a late-stage study, sending its shares up as much as 2%. The combination, when added to the drugmaker's tremelimumab therapy, also met the secondary goal of improving progression-free survival, the British drugmaker said. The triple combination delivered a broadly similar safety profile to the Imfinzi and chemotherapy combination and did not result in increased discontinuation of therapy, AstraZeneca said.
AstraZeneca Plc said on Monday that its cancer drug met the main goal of delaying the progression of a form of lung cancer. The drug, Imfinzi, when added to chemotherapy and the drugmaker's other cancer drug tremelimumab, significantly improved the survival of patients without the disease progressing, when compared to chemotherapy alone, the company said. Additional results from the trial with data on another goal of extending survival is expected in 2020, AstraZeneca said.
AstraZeneca shares traded higher Monday after the drugmaker said its key lung cancer treatment delayed progression of the deadly disease.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 24) AstraZeneca plc (NYSE: AZN ) (reacted to a beat-and-raise ...
The British pound hovered around a key technical level Thursday as markets awaited the European Union’s decision on whether to grant an extension to the U.K. to leaving the bloc.
European stocks gained on Thursday, with investors bidding auto makers and pharmaceuticals higher on better-than-forecast earnings.
Investing.com -- Here are the highlights of Thursday's regulatory releases from the London Stock Exchange. Please refresh for updates.
GlaxoSmithKline said U.S. regulators had approved its ovarian cancer treatment Zejula for wider use in some advanced cancers, in a boost to the British drugmaker's oncology portfolio as it competes with rival AstraZeneca. The U.S. Food and Drug Administration approval is for the drug's use in advanced ovarian, fallopian tube, or primary peritoneal cancer patients who have undergone at least three prior chemotherapy regimens and whose disease has come back. Zejula is currently approved as a maintenance therapy for adults with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer and whose tumours have completely or partially responded to platinum-based chemotherapy treatments.